Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Elevated circulating activin A levels in malignant pleural mesothelioma patients are related to cancer cachexia and poor response to platinum-based chemotherapy Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019
Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
The prognostic value of the expression of GST-π in response to chemotherapy in cytological and pathological specimens of patients with lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Late lung toxicity and serum cytokine profile in patients submitted to radio-chemotherapy for Hodgkin‘s disease (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 589s Year: 2007
Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Alterations of serum inflammatory biomarkers in the healthy and lung cancer patients before and post chemotherapy Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Improved results after preoperative concurrent chemotherapy and high dose radiation therapy in selected cases with stage III N2 lung cancer? Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer Source: Eur Respir J 2015; 46: 1773-1780 Year: 2015
The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease Source: Eur Respir J, 51 (4) 1800410; 10.1183/13993003.00410-2018 Year: 2018